Phase III study shows Cialis (Eli Lilly) plus finasteride provides benefits for Benign Prostatic Hyperplasia
A new Phase III study showed Cialis (tadalafil), from Eli Lilly and Co, co-administered with finasteride significantly improved scores on the International Prostate Symptom Score (IPSS), compared to placebo/finasteride, in men with lower urinary tract symptoms of Benign Prostatic Hyperplasia (LUTS/BPH) and enlarged prostates. On a pre-specified secondary measure, Cialis/finasteride also improved erectile function scores versus placebo/finasteride in those men who had both LUTS/BPH and erectile dysfunction (ED) at baseline.
Cialis/finasteride met the primary endpoint, significantly improving IPSS total scores through 12 weeks versus placebo/finasteride (-5.2 versus -3.8, p = 0.001). Cialis/finasteride also significantly improved IPSS total scores versus placebo/finasteride at 4 weeks (-3.9 versus -2.3, p<0.001) and 26 weeks (-5.5 versus -4.5, p="0.022)." data was presented at european association of urology congress.>0.001)>